6-bromo-4-methoxy-5-(methylthio)-2,2'-bipyridine | 205053-05-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-bromo-4-methoxy-5-(methylthio)-2,2'-bipyridine
• 英文别名: 2-Bromo-4-methoxy-3-methylsulfanyl-6-pyridin-2-ylpyridine
• CAS: 205053-05-0
• 化学式: C₁₂H₁₁BrN₂OS
• 分子量: 311.202
• InChiKey: IKPHQMMBROLKPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-bromo-4-methoxy-5-(methylthio)-2,2'-bipyridine 在 吡啶 、 正丁基锂 、 四甲基乙二胺 、 盐酸羟胺 作用下， 以 乙醚 、 乙醇 、 正己烷 为溶剂， 反应 2.25h， 生成 (2E)-4-甲氧基-3-甲硫基-2-(亚硝基亚甲基)-6-(2-吡啶基)-1H-吡啶
  参考文献：
  名称：

  First Syntheses of Caerulomycin E and Collismycins A and C. A New Synthesis of Caerulomycin A

  摘要：

  Caerulomycins produced by Streptomyces caeruleus, and collismycins more recently isolated from Streptomyces species, are bipyridinic molecules endowed with antibiotic and cytotoxic activities. The first syntheses of caerulomycin E (1), as well as new syntheses of caerulomycin A (2), are reported. Methodologies involving efficiently controlled reactions such as metalation and cross-coupling reactions have been developed from 2,2'-bipyridine. The functionalization at C-6 could be achieved by metalation of 2,2'-bipyridine N-oxides 5 and 12. 6-Halo-4-methoxy-2,2'-bipyridines (6, 10, 11) became key-molecules of these different pathways, and further functionalization at C-5 allowed the first syntheses of collismycins A (3) and C (4).

  DOI：

  10.1021/jo972022i
• 作为产物：
  描述：

  2,2′-二吡啶基 N-氧化物 在 硫酸 、 三溴化磷 、 potassium nitrate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 氯仿 为溶剂， 反应 6.0h， 生成 6-bromo-4-methoxy-5-(methylthio)-2,2'-bipyridine
  参考文献：
  名称：

  First Syntheses of Caerulomycin E and Collismycins A and C. A New Synthesis of Caerulomycin A

  摘要：

  Caerulomycins produced by Streptomyces caeruleus, and collismycins more recently isolated from Streptomyces species, are bipyridinic molecules endowed with antibiotic and cytotoxic activities. The first syntheses of caerulomycin E (1), as well as new syntheses of caerulomycin A (2), are reported. Methodologies involving efficiently controlled reactions such as metalation and cross-coupling reactions have been developed from 2,2'-bipyridine. The functionalization at C-6 could be achieved by metalation of 2,2'-bipyridine N-oxides 5 and 12. 6-Halo-4-methoxy-2,2'-bipyridines (6, 10, 11) became key-molecules of these different pathways, and further functionalization at C-5 allowed the first syntheses of collismycins A (3) and C (4).

  DOI：

  10.1021/jo972022i

文献信息

• USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS
  申请人：Martinez Gil Ana

  公开号：US20100048635A2

  公开（公告）日：2010-02-25

  The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.

  本发明涉及使用Collismycin及其衍生物作为细胞内氧化应激的抑制剂，以及它们用于制备治疗和/或预防氧化应激引起的疾病或病状的药物，尤其是神经退行性疾病，如阿尔茨海默病和帕金森病。
• Use of Collismycin and Derivatives Thereof as Oxidative Stress Inhibitors
  申请人：Martinez Gil Ana

  公开号：US20080275088A1

  公开（公告）日：2008-11-06

  The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.

  本发明涉及使用Collismycin及其衍生物作为细胞内氧化应激抑制剂及其用于制备治疗和/或预防氧化应激引起的疾病或症状的药物，特别是神经退行性疾病，如阿尔茨海默病和帕金森病。
• Use of collismycin and derivatives thereof as oxidative stress inhibitors
  申请人：Neuropharma S.A.

  公开号：EP1749552A1

  公开（公告）日：2007-02-07

  The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment of oxidative stress-induced diseases or conditions, specially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.

  本发明涉及科利霉素及其衍生物作为细胞氧化应激抑制剂的用途，以及它们用于制备治疗氧化应激引起的疾病或病症的药物，特别是神经退行性疾病，如阿尔茨海默氏症和帕金森氏症。
• US8067441B2
  申请人：——

  公开号：US8067441B2

  公开（公告）日：2011-11-29
• [EN] USE OF COLLISMYCIN AND DERIVATIVES THEREOF AS OXIDATIVE STRESS INHIBITORS<br/>[FR] UTILISATION DE LA COLLISMYCINE ET DE DERIVES DE CELLE-CI COMME INHIBITEURS DU STRESS OXYDATIF
  申请人：NEUROPHARMA SA

  公开号：WO2007017146A2

  公开（公告）日：2007-02-15

  [EN] The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer´s Disease and Parkinson's Disease.
  [FR] L'invention se rapporte à l'utilisation de la Collismycine et de dérivés de celle-ci en tant qu'inhibiteurs du stress oxydatif dans les cellules, ainsi qu'à l'utilisation de ces composés pour la préparation de médicaments destinés au traitement et/ou à la prévention de maladies ou d'affections résultant du stress oxydatif, en particulier les maladies neurodégénératives telles que la maladie d'Alzheimer et la maladie de Parkinson.